MBX
NASDAQMBX Biosciences Inc.
News25/Ratings12
News · 26 weeks67+100%
2026-03-012026-08-23
Mix2890d
- Insider10(36%)
- SEC Filings9(32%)
- Other5(18%)
- Earnings2(7%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- ANALYSTAnalyst resumed coverage on MBX Biosciences with a new price targetAnalyst resumed coverage of MBX Biosciences with a rating of Overweight and set a new price target of $88.00
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by MBX Biosciences Inc.SCHEDULE 13D/A - MBX Biosciences, Inc. (0001776111) (Subject)
- SECSEC Form 10-Q filed by MBX Biosciences Inc.10-Q - MBX Biosciences, Inc. (0001776111) (Filer)
- SECMBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate HighlightsOne-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, support potential for once-monthly dosing; data from 12-week MAD (Part C) on track for Q4 2026 Nomination of development candidate MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, further expands obesity portfolio $418.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX),
- INSIDERChief Medical Officer Azoulay Salomon sold $24,335 worth of shares (370 units at $65.77), decreasing direct ownership by 3% to 14,399 units (SEC Form 4) to satisfy withholding obligation4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- INSIDERChief Financial Officer Smither John W was granted 28,000 shares (SEC Form 4)4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERPresident and CEO Hoerter Steven L. was granted 71,000 shares, increasing direct ownership by 595% to 82,938 units (SEC Form 4)4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- PRAttovia Therapeutics Appoints John W. Smither to Board of DirectorsSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,
- SECSEC Form 8-K filed by MBX Biosciences Inc.8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of GrowthCARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the C
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)
- SECMBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismResponder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function) High retention rate with 90% of patients entering the OLE remaining in the study at one year Canvuparatide was generally well tolerated with no new safety signals during the OLE PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure Phase 3 pivotal trial remains on track to initiate in Q3 2026 Company to host conference call tod
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Pescovitz Ora H.4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Heron Patrick J4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoerter Steven L.4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Ryder Steven4 - MBX Biosciences, Inc. (0001776111) (Issuer)
MBX FAQ
6 questionsWhere does MBX stock trade?
MBX Biosciences Inc. (MBX) is listed on NASDAQ.What sector and industry is MBX in?
MBX Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MBX Biosciences Inc. go public?
MBX Biosciences Inc. (MBX) completed its IPO in 2024.What are analysts saying about MBX?
MBX Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-08-21. Recent price targets range from $1800.00 to $3800.00.What companies are similar to MBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MBX side-by-side with any of them on Quantisnow.How can I track MBX on Quantisnow?
Quantisnow aggregates MBX Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBX to receive live email and push alerts on every new disclosure.